Stanley-Laman Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stanley-Laman Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,023	Closed	-$219K	–	266
2019 Q2	$219K	Buy	+3,023	New	+$232K	0.05%	263
2019 Q1	–	Sell	-2,875	Closed	-$210K	–	259
2018 Q4	$210K	Buy	+2,875	New	+$221K	0.06%	238
2015 Q3	–	Sell	-3,000	Closed	-$360K	–	322
2015 Q2	$360K	Hold	3,000	–	–	0.07%	235
2015 Q1	$313K	Hold	3,000	–	–	0.06%	248
2014 Q4	$291K	Hold	3,000	–	–	0.06%	265
2014 Q3	$234K	Buy	+3,000	New	+$194K	0.05%	262
2014 Q2	–	Sell	-3,000	Closed	-$201K	–	291
2014 Q1	$201K	Buy	+3,000	New	+$232K	0.04%	308

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Stanley-Laman Group's ALNY Position: Q3 2019 in Review

Stanley-Laman Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2019, closing a stake of 3,023 shares — an estimated $219K sold.

Stanley-Laman Group first reported a position in ALNY in Q1 2014 and held it in 7 quarters. The position peaked at $360K in Q2 2015. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Stanley-Laman Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Stanley-Laman Group sold 3,023 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $219K.
Stanley-Laman Group first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Stanley-Laman Group's Alnylam Pharmaceuticals position peaked at $360K in Q2 2015.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.